Papers published in PubMed in last 60 days

(Data retrieved on Thu Jun 11 17:00:24 IST 2015 )



  1. Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole.
  2. The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERalpha expression and enhances hormonal therapy for breast cancer.
  3. Epigenetics in acute kidney injury.
  4. Histone Deacetylase Inhibition Rescues Maternal Deprivation-Induced GABAergic Metaplasticity through Restoration of AKAP Signaling.
  5. Epigenetics of obesity: beyond the genome sequence.
  6. You are what you eat: O-linked N-acetylglucosamine in disease, development and epigenetics.
  7. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.
  8. Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids.
  9. Epigenetics. Exceptional epigenetics in the brain.
  10. Tissue-specific epigenetics in gene neighborhoods: Myogenic transcription factor genes.
  11. Epigenetics of Notch1 regulation in pulmonary microvascular rarefaction following extrauterine growth restriction.
  12. The Mitochondrial Side of Epigenetics.
  13. Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple negative breast cancer cells.
  14. [Antiapoptotic gene bcl-2 prevents cellular senescence program reactivation induced by histone deacetylase inhibitor sodium butyrate in E1A and cHa-ras transformed rat fibroblasts].
  15. Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway.
  16. Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system.
  17. Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.
  18. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
  19. Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue.
  20. Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy.
  21. Epigenetics, Darwin and Lamarck.
  22. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
  23. Contribution of epigenetics in diabetic retinopathy. with diabetes becoming at a risk of developing retinopathy, diabetic retinopathy
  24. Histone deacetylase HDAC1 downregulates transcription of the serotonin transporter (5-HTT) gene in tumor cells.
  25. [Histone deacetylase inhibitors cause the TP53-dependent induction of p21/Waf1 in tumor cells carrying mutations in TP53].
  26. A miniaturized readout strategy for endogenous histone deacetylase activity. characterize due to their poor accessibility. We have developed a miniaturized
  27. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with
  28. Reproductive endocrinology: Epigenetics in pregnancy.
  29. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group.
  30. Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
  31. Histone deacetylase inhibitors: a review on class-I specific inhibition.
  32. Recent developments in epigenetics of acute and chronic kidney diseases.
  33. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
  34. EGCG-mediated autophagy flux has a neuroprotection effect via a class III histone deacetylase in primary neuron cells.
  35. A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors.
  36. Introduction to progress and promise of epigenetics for diagnosis and therapy in cancer.
  37. Epigenetics of Posttraumatic Stress Disorder: Current Evidence, Challenges, and Future Directions.
  38. The role of epigenetics in the endothelial cell shear stress response and atherosclerosis.
  39. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
  40. The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia.
  41. Inhibiting histone deacetylase 6 partly protects cultured rat cortical neurons from oxygenglucose deprivationinduced necroptosis.
  42. Emerging Interplay of Genetics and Epigenetics in Gliomas: A New Hope for Targeted Therapy.
  43. Structural diversity of the epigenetics pocketome.
  44. Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.
  45. Treatment of chronic kidney diseases with histone deacetylase inhibitors.
  46. GLAST But Not Least-Distribution, Function, Genetics and Epigenetics of L-Glutamate Transport in Brain-Focus on GLAST/EAAT1.
  47. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.
  48. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
  49. Stroke Induces Nuclear Shuttling of Histone Deacetylase 4.
  50. Building up and knocking down: An emerging role for epigenetics and proteasomal degradation in systems consolidation.
  51. Epigenetics and pharmacology.
  52. Epigenetics Meets Immune Checkpoints.
  53. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
  54. Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
  55. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
  56. The role of AP-1 and epigenetics in ALCL.
  57. Epigenetics and Osteoarthritis.
  58. Neuroscience, epigenetics and the intergenerational transmission of social life: exploring expectations and engagements.
  59. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
  60. The histone deacetylase sirtuin 2 is a new player in the regulation of platelet function.
  61. [Epigenetics and drug addiction: a focus on MeCP2 and on histone acetylation].
  62. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.
  63. Correction: Histone Deacetylase Inhibition Enhances Tissue Plasminogen Activator Release Capacity in Atherosclerotic Man.
  64. Epigenetics. Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing.
  65. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
  66. A role for epigenetics in the formation of chromosome translocations in acute leukemia.
  67. The role of epigenetics in personalized medicine: challenges and opportunities.
  68. Neuronal developmental gene and miRNA signatures induced by histone deacetylase inhibitors in human embryonic stem cells.
  69. Heart failure: advanced development in genetics and epigenetics.
  70. HDACiDB: a database for histone deacetylase inhibitors.
  71. Analysis of class I and II histone deacetylase gene expression in human leukemia.
  72. Role of chromatin structure modulation by the histone deacetylase inhibitor trichostatin A on the radio-sensitivity of ataxia telangiectasia.
  73. Barcelona conference on epigenetics and cancer: 50 years of histone acetylation.
  74. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
  75. [Cigarette smoke extract induces senescence of murine skeletal muscle cells by oxidative stress-induced down-regulation of histone deacetylase 2].
  76. In reply-Epigenetics and Childhood Obesity.
  77. Epigenetics and childhood obesity.
  78. Epigenetics in the wild.
  79. Epigenetics in lung cancer diagnosis and therapy. initiation and progression of lung cancer is the result of the interaction
  80. Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model.
  81. Murine hematopoietic stem cell dormancy controlled by induction of a novel short form of PSF1 by histone deacetylase inhibitors.
  82. Editorial: Genetics and epigenetics of fetal alcohol spectrum disorders.
  83. (P039) outcomes of patients with glioblastoma receiving concurrent radiation treatment and antiepileptic agents with histone deacetylase inhibitor activity.
  84. [Histone deacetylase 6: structure, functions and development of selective inhibitors].
  85. Regulation of flowering time by the histone deacetylase HDA5 in Arabidopsis.
  86. The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.
  87. Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways.
  88. Environmental Epigenetics and a Unified Theory of the Molecular Aspects of Evolution: A Neo-Lamarckian Concept that Facilitates Neo-Darwinian Evolution.
  89. Epigenetics of aging.
  90. The histone deacetylase SIRT6 controls embryonic stem cell fate via TET-mediated production of 5-hydroxymethylcytosine.
  91. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
  92. Manipulation of B-cell responses with histone deacetylase inhibitors.
  93. The genetics of loneliness: linking evolutionary theory to genome-wide genetics, epigenetics, and social science.
  94. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
  95. Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
  96. Diverse involvement of EZH2 in cancer epigenetics.
  97. Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
  98. Histone Deacetylase Inhibitor Romidepsin Inhibits de novo HIV-1 Infections.
  99. Emerging approaches for histone deacetylase inhibitor drug discovery.
  100. Hydroxamate-Based Histone Deacetylase Inhibitors Can Protect Neurons from Oxidative Stress via a Histone Deacetylase-Independent Catalase-Like Mechanism.
  101. Epigenetics, society, and bio-objects.
  102. Mitochondrial epigenetics: an overlooked layer of regulation?
  103. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
  104. Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, through down-regulating EGFR expression.
  105. A phosphorescent rhenium(i) histone deacetylase inhibitor: mitochondrial targeting and paraptosis induction.
  106. Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.
  107. Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease. digestive system. A mutation in the CF transmembrane conductance regulator (CFTR)
  108. Marine Actinomycetes as potential source for histone deacetylase inhibitors and epigenetic modulation.
  109. Restoring histone deacetylase activity by waste product release. A view from molecular mechanics simulations with mammalian HDAC8.
  110. Correction: autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
  111. The epigenetics of multiple sclerosis and other related disorders.
  112. Epigenetics: An Emerging Framework for Advanced Practice Psychiatric Nursing.
  113. Histone deacetylase inhibitors: potent anti-leukemic agents.
  114. Deletion of Histone Deacetylase 7 in Osteoclasts Decreases Bone Mass in Mice by Interactions with MITF.
  115. Epigenetics: Characterizing enhancers with dCas9.
  116. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
  117. Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement.
  118. [The histone deacetylase sirtuins modulate cell autophagy in cardiovascular diseases].
  119. The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.
  120. Is There a Link Between Expression Levels of Histone Deacetylase/Acetyltransferase in Mouse Sperm and Subsequent Blastocyst Development?
  121. Chemical tools for probing histone deacetylase (HDAC) activity.
  122. The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.